Ischemic heart disease

Cardiovascular disease is the leading global cause of death, accounting for over 17 million deaths per year. The number of cardiovascular deaths is expected to grow to more than 23 million by 2030, according to a report from the American Heart Association.1 In 2011 nearly 787,000 people died from heart disease, stroke and other cardiovascular diseases in the United States. Two new approaches have been identified that have the potential of added benefits to the current therapeutic strategies. The first focuses on enhancing the heart/myocardium’s tolerance to ischemia-reperfusion injury using cardiac conditioning. The second approach is to create an environment within the heart muscle that will result in repair of the damaged myocardium.

Peripheral arterial diseases / critical limb ischemia

Peripheral arterial disease (PAD) is commonly referred to ischemia of extremities secondary to atherosclerotic occlusion. More than 25 million patients suffer from PAD in the developed countries. An additional cause of PAD is vasculitis including thromboangitis obliterance (TAO) (Buerger’s disease), which can also lead to severe limb ischemia. Chronic critical limb ischemia (CLI) is defined as the end-stage of lower limb ischemia. The clinical manifestations consist of rest pain and/or skin ulceration or gangrene.


      Why mesenchymal stem cells treatment?

Although the sample size in work of Bartolucci et al. was small (15 controls and 15 HF patients treated with UC-MSCs) to establish either safety or efficacy, the echocardiographic and cardiac MRI evaluations demonstrated improvements in ejection fraction, starting at 3 months, and persisting through 12 months. The patients treated with placebo did not improve in either left ventricular ejection fraction or clinical functional class. As indicated by the authors, it is tempting to speculate that the robust paracrine secretion of various factors, including hepatocyte growth factor, might play an important role in mediating the therapeutic effects of the UC-MSCs. A cell-based therapy could offer additional clinical benefits for post-ischemic heart by improving revascularization along with structural and functional properties.


Impact of therapy

The Stem Cell treatment of such conditions in QR Health Solutions is provided within CardioQR program.

Results of the therapy always depends on a condition and individual profile. Expected results:

  • reduce inflammation
  • promote tissue regeneration
  • increased energy
  • reduced medications
  • thus increasing the quality of life.

Your treatment plan in QR Health Solutions:

Day 1 Examination

Heart ultrasound and heart rhythm examination, MRI and CT scan if needed

Treatment plan

The road-map of treatment according to health condition and diseases detected

Day 2 Therapy

Injections of expanded allogeneic mesenchymal stem cells

Day 3 Therapy

Repetitive administration, monitoring the result. Visit of our cardiologist, making plan for discharge, recommendation are given.

Day 4 Recovery

Clinical examination, planning of further observation


Just fill the application and one of our specialists will contact you by e-mail, phone, or any other convenient way for you. We will be happy to answer all your questions and provide the necessary information.